JCO Global Oncology最新文献

{"title":"Socioeconomic Burden of Ovarian Cancer in 11 Countries.","authors":"Brian Hutchinson, Mikis Euripides, Frances Reid, Gavin Allman, Lily Morrell, Garrison Spencer, Andre Ilbawi, Filip Meheus, Hesham Gaafar, Raffaella Casolino","doi":"10.1200/GO-24-00313","DOIUrl":"10.1200/GO-24-00313","url":null,"abstract":"<p><strong>Purpose: </strong>Ovarian cancer remains among the most aggressive tumors with the lowest survival probability. Projections are that ovarian cancer will claim more than 8 million lives between 2022 and 2050 without better prevention or control measures.</p><p><strong>Methods: </strong>We built an Excel-based instrument that uses a prevalence-based cost-of-illness approach and a societal perspective to estimate the burden of ovarian cancer. The instrument leverages data from editions of the World Ovarian Cancer Coalition's Every Woman Study, contains a micro-costing framework to assess the resources and costs of providing care, and uses data from novel systematic reviews and meta-analyses conducted to estimate the effect of ovarian cancer on patient labor productivity outcomes and the time caregivers devote to caring for people living with the disease.</p><p><strong>Results: </strong>Across 11 countries, we estimated US dollars 70 billion in socioeconomic losses attributable to ovarian cancer. Health expenditures to cover treatment in the first 2 years after diagnosis were 7, 41, and 118 times total health spending per capita in high-, upper-middle-, and low- and lower-middle countries, respectively. Patients spent 3,663 years traveling to or receiving treatment. Women lost labor productivity equivalent to 2.5 million workdays due to ill-health from ovarian cancer, and 9,403 women living with ovarian cancer or survivors were estimated to be missing from the workforce. Caregivers spent 17,112 person-years providing practical support to patients-an average of 33 days per woman living with ovarian cancer.</p><p><strong>Conclusion: </strong>This study is the first to quantify the social and economic burden of ovarian cancer in 11 countries and highlights its significant cost and defines actions needed to improve ovarian cancer outcomes.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2400313"},"PeriodicalIF":3.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143468187","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiotherapy and Nuclear Medicine Equipment Shortages in Vietnam: A Critical Gap in Cancer Care.","authors":"Dang Van Nguyen, Manh Duy Pham, Thai Huu Hoang, Binh Thanh Nguyen","doi":"10.1200/GO-24-00530","DOIUrl":"10.1200/GO-24-00530","url":null,"abstract":"<p><strong>Purpose: </strong>The aim of this study was to evaluate the current availability and distribution of radiotherapy (RT) and nuclear medicine equipment in Vietnam, focusing on the shortage of linear accelerators (LINACs), positron emission tomography/computed tomography (PET/CT) scanners, and brachytherapy units. The study seeks to quantify these shortages and highlight the implications for cancer treatment access and outcomes.</p><p><strong>Methods: </strong>Data were collected from 50 hospitals across Vietnam that provide RT services or nuclear medicine imaging. The availability of LINACs, PET/CT devices, brachytherapy units, and other essential equipment was assessed, alongside patient loads and machine utilization rates. National data were compared with the standard in developed countries, with a particular focus on the International Atomic Energy Agency's (IAEA) recommendations for RT infrastructure.</p><p><strong>Results: </strong>Vietnam has a total of 82 LINACs, resulting in a LINAC density of 0.82 per million people, which is far below the standard in developed countries of 4-8 per million. Of the existing LINACs, 43% are outdated and unable to deliver advanced RT techniques such as volumetric modulated arc therapy. Additionally, the country has only 12 PET/CT scanners and three cyclotrons, which limits access to early cancer diagnosis and treatment planning. The central region of Vietnam is particularly underserved, with only 1 PET/CT device and limited access to brachytherapy services. Long wait times for RT-often up to 2 weeks-are common, leading to delayed treatments and reduced treatment efficacy. Patients, particularly those with conditions requiring timely RT after chemotherapy, face increased risks because of these delays.</p><p><strong>Conclusion: </strong>The shortage of modern RT and nuclear medicine equipment in Vietnam critically limits timely access to cancer treatment, affecting patient outcomes and placing a heavy burden on health care providers. Expanding access to advanced RT technology through government investment, public-private partnerships, and international collaborations with organizations such as the IAEA could alleviate these challenges. Increasing Vietnam's RT capacity is essential for improving cancer care outcomes and managing the rising burden of cancer across the country.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2400530"},"PeriodicalIF":3.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143523379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evacuating Patients With Pediatric Cancer From Ukraine: Impact on Medical Care Capacity in Poland.","authors":"Aleksandra Oszer, Khrystyna Kliuchkivska, Julia Kołodrubiec, Andriy Sopilnyak, Marta Salek, Marcin W Włodarski, Małgorzata Dutkiewicz, Zuzanna Nowicka, Maryna Krawczuk-Rybak, Jan Styczyński, Katarzyna Machnik, Ninela Irga-Jaworska, Agnieszka Mizia-Malarz, Grażyna Karolczyk, Szymon Skoczeń, Walentyna Balwierz, Katarzyna Drabko, Katarzyna Mycko, Katarzyna Derwich, Radosław Chaber, Tomasz Ociepa, Jarosław Peregud-Pogorzelski, Bożenna Dembowska-Bagińska, Paweł Łaguna, Krzysztof Kałwak, Tomasz Szczepański, Anna Raciborska, Piotr Czauderna, Asya Agulnik, Wojciech Młynarski","doi":"10.1200/GO.24.00046","DOIUrl":"10.1200/GO.24.00046","url":null,"abstract":"<p><strong>Purpose: </strong>Soon after the Russian invasion of Ukraine in February 2022, an initiative was organized to evacuate Ukrainian children with cancer, most initially to Poland. This study assessed the impact of this rapid increase in clinical need on the Polish system of pediatric cancer care.</p><p><strong>Methods: </strong>This multicenter longitudinal approach was performed among all 19 Polish Pediatric Oncology Centers (PPOCs). We compared PPOC capacity before the invasion with that during the first 11 weeks after the invasion, using three ratios: patients to physicians (PtP), patients to nurses (PtN), and patients to beds (PtB). In addition, we used national data from an ongoing leukemia clinical trial to assess differences between the two study periods in the time required to comply with protocol-indicated medical procedures requiring general anesthesia.</p><p><strong>Results: </strong>During the study period, 237 Ukrainian refugee children with cancer were treated in PPOCs; 60% of them arrived during the first 21 days of the war. The relative increase in patients varied significantly among the PPOCs, ranging from 42% to 460%. The average PtP, PtN, and PtB ratios increased significantly by 85%, 131%, and 105%, respectively. The portion of patients experiencing a delay in obtaining medical procedures requiring general anesthesia increased from 15% before the war to 18.2% (<i>P</i> = .043).</p><p><strong>Conclusion: </strong>Because of the large number of Ukrainian children with cancer were evacuated to Poland, capacity of PPOCs was reduced, affecting cancer care for all patients. Maintaining standards of pediatric oncology care in Poland would not be possible without further patient referral to medical facilities around the world by international humanitarian collaborative action.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2400046"},"PeriodicalIF":3.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11892610/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143414326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Scoping Review of the Impact of Culture on the Effectiveness of Quality Improvement Programs.","authors":"Carlos Frederico Pinto, Robin Jones, Francisco Gutierrez-Delgado, Julia Tomkins, Martins Fideles Santos Neto","doi":"10.1200/GO.24.00035","DOIUrl":"10.1200/GO.24.00035","url":null,"abstract":"<p><strong>Purpose: </strong>Cultural differences and their effect on international collaboration have been studied in several industries but only recently in health care. Understanding these differences can significantly influence the outcomes of ASCO's international co-operation initiatives focused on quality improvement.</p><p><strong>Methods: </strong>This manuscript is a scoping literature review examining how cultural differences influence the quality and safety of oncology care, and what strategies can be implemented to improve quality and outcomes in multicultural settings using cultural traits outlined by Hofstede's dimensions of culture. Power distance index (PDI; the ability to speak up without embarrassment) emerged in other industries as the most relevant trait affecting quality and team performance.</p><p><strong>Results: </strong>Few publications are available addressing such perspective, and the literature to date revealed that cultures with small PDI tend to perform better in health care safety and quality, and leadership behavior is a dominant feature in this condition. New techniques adopting psychological safety practices can mitigate cultural traits like PDI that hinder quality practices in oncology.</p><p><strong>Conclusion: </strong>The authors consider that psychological safety practices are a culturally sensitive strategy to ASCO's Quality Programs that can mitigate local cultural barriers and develop leadership behaviors that enable safety and quality strategies, and foster more effective international collaboration in ASCO Quality Programs in the future.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2400035"},"PeriodicalIF":3.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143468184","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Childhood Cancer Survivorship Care in Limited Resource Settings: A Narrative Review and Strategies to Promote Global Health Equity.","authors":"David H Noyd, Ana Carolina Izurieta-Pacheco, Rizine Mzikamanda, Nana Nakiddu, Dao Thi Thanh An, Bounpalisone Souvanlasy, Ritu Bhalla, Chandan Kumar, Poonam Bagai, Remziye Semerci, Tuba Arpaci, Kristin Schroeder, Adekemi Oyewusi, Florencia Moreno, Liliana Vásquez, Soad Fuentes-Alabí","doi":"10.1200/GO-24-00274","DOIUrl":"10.1200/GO-24-00274","url":null,"abstract":"<p><p>The WHO Global Initiative for Childhood Cancer, prompted by the marked inequity of survival across the globe, aims to increase survival rates in low- and middle-income countries to 60% by 2030. In tandem with this effort, implementing survivorship-focused care is crucial to mitigate late effects and prevent early mortality beyond the 5-year survival end point. The observed burden of secondary malignancies, cardiovascular disease, and other chronic health conditions in adult survivors of childhood cancer in high-income countries provides guidance to generate evidence in limited-resource settings. The implementation of risk stratification tools, population health management, and development of contextually relevant health care delivery models, within the current landscape of survivorship care in Latin America, Africa, and Asia as examples, are vital to continue the momentum to ensure equitable care and quality of life for all survivors of childhood cancer. This narrative review informed by expert opinion serves as a call to action for survivors, advocacy groups, health professionals, health systems, governments, and global organizations to look beyond the 5-year survival benchmark.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2400274"},"PeriodicalIF":3.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11892615/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143414307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Spotlight on Lung Cancer Disparities in India.","authors":"Manas Gunani, Rahul Winayak, Anisha Agarwal, Aruni Ghose, Rounak Das, Kumar Prabhash, Vanita Noronha, Giuseppe Luigi Banna, Stergios Boussios, Swarupa Mitra","doi":"10.1200/GO-24-00327","DOIUrl":"10.1200/GO-24-00327","url":null,"abstract":"","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2400327"},"PeriodicalIF":3.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11892605/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143370663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Somatic Landscape of Oncogenic Variants Across the Main Cancer Subtypes in Latin America: A Narrative Review.","authors":"Talia Wegman-Ostrosky, Lucia Taja-Chayeb, Zyanya Lucia Zatarain-Barrón, Catalina Trejo-Becerril, Daniela Shveid Gerson, Isabel Espino-Gutiérrez, Andrea Gutiérrez-Lara, Andrés Yesid Bonilla Salcedo, Mistral Castellanos Mares, José Elias García-Ortiz, Carla Daniela Robles-Espinoza, Alejandro Ruíz-Patiño","doi":"10.1200/GO-24-00389","DOIUrl":"10.1200/GO-24-00389","url":null,"abstract":"<p><p>Variations in somatic genetic alterations can be observed across different cancer types and diverse populations. Understanding the frequency of oncogenic variants in specific populations helps elucidate carcinogenesis and risk factors, with somatic variants often serving as treatment markers. Data regarding the somatic landscape across the main tumor subtypes in patients from Latin America and the Caribbean (LAC) have increased recently, highlighting important differences from contrasting populations in North America, Europe, and Asia. Many of these differences have pressing implications regarding screening, risk factor management, targeted therapies, and health care policy. This review aims to synthesize the existing information on somatic oncogenic variants in patients' tumors from LAC. We included the frequency of somatic oncogenic variants of the most frequent tumors in LAC: prostate cancer, female breast cancer, colon cancer, gastric cancer, and lung cancer. Furthermore, we add information from tumors that are relevant in LAC because of their high incidence, specific subtypes, or aggressive phenotypes, namely gallbladder cancer, acral melanoma, and hematologic neoplasms, respectively. The data highlight distinct differences in the reported prevalences of various somatic variants across a spectrum of neoplasms. Moreover, it demonstrates that an extensive number of genetic and molecular studies have been carried out in the region, improving the level of characterization for this complex, admixed population. Nonetheless, data from many individual countries are still scarce or altogether missing, underscoring the need to establish collaborative groups to further advance progress in LAC. The need for further comprehensive research in the area should not be substituted with data from other regions as we seek to empower the choices to improve our health care outlook.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2400389"},"PeriodicalIF":3.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143527775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Characteristics of Toxicities of Immune Checkpoint Inhibitors and Their Impact on Efficacy in Solid Cancers: An Analysis of Real-World Data in Moroccan Patients.","authors":"Badiaa Batlamous, Sihame Lkhoyaali, Loubna Omri, Magaly-Gwen-Farnely Nguema-Mipaka, Mohamed Khalis, Hanane Inrhaoun, Sarah Naciri, Ibrahim El Ghissassi, Hind Mrabti, Saber Boutayeb, Hassan Errihani","doi":"10.1200/GO-24-00312","DOIUrl":"10.1200/GO-24-00312","url":null,"abstract":"<p><strong>Purpose: </strong>Patients receiving immune checkpoint inhibitors (ICIs) may induce immune-related adverse events (irAEs). This study aimed to evaluate the toxicity induced by ICIs and explore the correlation between efficacy and toxicity in a Moroccan population.</p><p><strong>Methods: </strong>We conducted a prospective study of patients with solid tumors who received pembrolizumab or atezolizumab at the <i>National Institute of Oncology, Rabat</i> from July 2018 to December 2023. We identified irAEs according to ASCO 2021 guidelines and graded them according to the Common Terminology Criteria for Adverse Events Version 4.0. Efficacy with respect to progression-free survival (PFS) and overall survival (OS) was determined. A Cox regression model was used to determine the association between irAEs and survival.</p><p><strong>Results: </strong>Eighty-six patients with solid tumors who received ICIs were included. The primary tumor types were lung (40.7%), skin (29.1%), and GI cancer (14%). The ICIs most commonly used included pembrolizumab (67.4%) and atezolizumab (32.6%). ICIs were used as monotherapy (77.9%) or in combination (22.1%). A total of 58 (67.4%) patients presented any kind of irAEs. The most common toxicities in both the monotherapy and combination groups were GI, with rates of 25.3% and 31.5%, respectively. Patients with irAEs showed significantly longer median PFS compared with those without irAEs (9 <i>v</i> 3.6 months; hazard ratio [HR], 0.5 [95% CI, 0.32 to 0.99]; <i>P</i> = .04). The median OS was longer in patients with irAEs than in those without irAEs but was not statistically significant (19 <i>v</i> 10.3 months; HR, 0.8 [95% CI, 0.39 to 1.7]; <i>P</i> = .5).</p><p><strong>Conclusion: </strong>Our results indicated that ICIs have the potential to induce irAEs in patients with solid tumors. These adverse effects were commonly GI. The development of irAEs was associated with improved effectiveness of ICI treatment across different malignancies.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2400312"},"PeriodicalIF":3.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143523376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Overall Survival and Economic Impact of Triple-Negative Breast Cancer in Brazilian Public Health Care: A Real-World Study.","authors":"André Mattar, Marcelo Antonini, Andressa Gonçalves Amorim, Marina Diógenes Teixeira, Cristiano Augusto Andrade de Resende, Francisco Pimentel Cavalcante, Felipe Zerwes, Renata Arakelian, Eduardo de Camargo Millen, Fabricio Palermo Brenelli, Antonio Luiz Frasson, Renata Montarroyos Leite, Luiz Henrique Gebrim","doi":"10.1200/GO-24-00340","DOIUrl":"10.1200/GO-24-00340","url":null,"abstract":"<p><strong>Purpose: </strong>Triple-negative breast cancer (TNBC) presents notable treatment difficulties, especially in the public health care systems of low- and middle-income countries where access to advanced therapies is restricted. This study investigates TNBC's clinical, epidemiologic, and economic effects on survival within Brazil's public health care system.</p><p><strong>Methods: </strong>We conducted a retrospective cohort study of patients with TNBC treated between 2010 and 2019. Overall survival (OS) rates by stage were analyzed across various patient groups, including those receiving neoadjuvant or adjuvant treatment, patients with or without complete pathologic response, Black and non-Black patients, and those treated with or without carboplatin-based therapy. Cox proportional hazards models were applied to estimate hazard ratios (HRs) with 95% CIs, and annual treatment costs were calculated per stage.</p><p><strong>Results: </strong>Among 1,266 patients with TNBC, 710 met eligibility criteria. Kaplan-Meier analysis indicated stage II patients had a 47% lower mortality risk than stage III (HR, 0.53 [95% CI, 0.33 to 0.85]; <i>P</i> = .009). Patients in the adjuvant treatment group had a reduced risk (HR, 0.48 [95% CI, 0.34 to 0.69]) compared with the neoadjuvant group. Achieving complete pathologic response (pCR) greatly improved OS (HR, 0.21 [95% CI, 0.11 to 0.43]; <i>P</i> < .001). Black patients had better survival rates than non-Black (HR, 0.58 [95% CI, 0.40 to 0.86]; <i>P</i> = .006). Carboplatin use did not significantly affect OS (HR, 0.96 [95% CI, 0.65 to 1.43]; <i>P</i> = .857). The average monthly cost for systemic TNBC treatment increased with disease progression, from $101.87 in US dollars (USD) for stage I to $314.77 USD for stage IV second-line therapy.</p><p><strong>Conclusion: </strong>This study provides insight into TNBC in Brazil's public health system, showing that OS decreases with disease progression but is higher among Black patients. pCR and adjuvant therapy improve survival, although costs increase significantly at advanced stages, highlighting the economic burden of late-stage TNBC management.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2400340"},"PeriodicalIF":3.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143468170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment and Outcomes of Pancreatic Cancer in Armenia: A Retrospective Study From Resource-Limited Settings.","authors":"Elen Baloyan, Davit Zohrabyan, Liana Safaryan, Armen Avagyan, Lilit Harutyunyan, Vardan Bardakhchyan, Jemma Arakelyan, Amalya Sargsyan, Martin Harutyunyan, Mariam Mailyan, Gevorg Tamamyan, Samvel Bardakhchyan","doi":"10.1200/GO.24.00217","DOIUrl":"10.1200/GO.24.00217","url":null,"abstract":"<p><strong>Purpose: </strong>Pancreatic cancer is one of the deadliest cancers in the world. In Armenia, it is 12th by incidence. The aim of this study is to evaluate treatment and outcomes of pancreatic cancer in Armenia during the past 12 years.</p><p><strong>Methods: </strong>This is a retrospective study with data from three oncology centers in Armenia: \"Muratsan\" Hospital of Yerevan State Medical University, Mikaelyan institute of surgery, and Yeolyan Hematology and Oncology Center. The information was obtained from the medical records of the patients with pancreatic cancer treated at these centers during January 1, 2010-January 1, 2022. Log-rank test and Kaplan-Meier curves were used for survival analysis. Cox regression analysis was performed for identification of main prognostic factors.</p><p><strong>Results: </strong>Of 70 patients involved in the final analysis, 45.7% was female. The median age at diagnosis was 63 years. The median follow-up time was 11 months (range, 2-146). A total of 11.4% of patients had stage I-II, 27.1% had stage III, and 60% had stage IV disease. The main independent prognostic factor for overall survival (OS) was the TNM stage, whereas grade of the tumor was not significant. The median OS was 11 months (range, 2-169 months): In stages I-III, patients who had surgery (44.4%) lived significantly longer than those who did not (20 <i>v</i> 11 months; <i>P</i> = .008). Main chemotherapy regimens were 5-fluorouracil, oxaliplatin, folinic acid and irinotecan (41.4%) and gemcitabine plus capecitabine (38.6%). No significant survival difference was found between these groups (13 <i>v</i> 11 months; <i>P</i> = .162).</p><p><strong>Conclusion: </strong>Survival of patients with pancreatic cancer in Armenia is dismal, not exceeding 1 year. Hopefully, further research in the field and new treatment modalities will improve the situation.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2400217"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143064671","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}